Search

Your search keyword '"Gardini, Andrea Casadei"' showing total 136 results

Search Constraints

Start Over You searched for: Author "Gardini, Andrea Casadei" Remove constraint Author: "Gardini, Andrea Casadei"
136 results on '"Gardini, Andrea Casadei"'

Search Results

2. Correction to: A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY tract cancers (BTC) at high risk for recurrence: PURITY study

3. A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study

5. Potential feasibility of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma treated with tyrosine-kinase inhibitors

6. Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma

7. Identification of PRMT5 as a therapeutic target in cholangiocarcinoma.

8. Hepatocellular Cancer

9. Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment

10. Circulating microRNAs as biomarkers for stratifying different phases of liver cancer progression and response to therapy.

11. Is there an association between commonly employed biomarkers of liver fibrosis and liver stiffness in the general population?

13. Hepatocellular Cancer

14. Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments

15. Deep learning predicts sensitivity to atezolizumab-bevacizumab from digital slides of hepatocellular carcinoma

16. Incidence and risk factors of esophagogastric varices bleeding in patients with advanced hepatocellular carcinoma treated with lenvatinib

18. Correction to: Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE‑2 Study

20. Defining and predicting textbook outcomes for perihilar cholangiocarcinoma: analysis of factors improving achievement of desired postoperative outcomes.

21. Recalibrating survival prediction among patients receiving trans‐arterial chemoembolization for hepatocellular carcinoma

22. Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma

23. The genomic landscape of IDH1 mutant intrahepatic cholangiocarcinoma: a multicentre comprehensive analysis

24. Proteomic analysis of bile in the rat thioacetamide model reveals new mechanisms in human cholangiocarcinogenesis

25. Plasma cell-free DNA methylation as biomarker for hepatocellular carcinoma

26. Effect of direct-acting antivirals on future occurrence of hepatocellular carcinoma in compensated cirrhotic patients

27. Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment

28. THU-145 - Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments

29. THU-131 - Incidence and risk factors of esophagogastric varices bleeding in patients with advanced hepatocellular carcinoma treated with lenvatinib

31. LBO-04 - Deep learning predicts sensitivity to atezolizumab-bevacizumab from digital slides of hepatocellular carcinoma

33. Hemangioblastoma of the Gastrointestinal Tract: A First Case

35. Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows

36. SAT180 - The genomic landscape of IDH1 mutant intrahepatic cholangiocarcinoma: a multicentre comprehensive analysis

37. FRI554 - Proteomic analysis of bile in the rat thioacetamide model reveals new mechanisms in human cholangiocarcinogenesis

38. FRI222 - Plasma cell-free DNA methylation as biomarker for hepatocellular carcinoma

39. Preoperative Chemotherapy and Resection Margin Status in Colorectal Liver Metastasis Patients: A Propensity Score–Matched Analysis

41. THU-448-Multicentric prospettive study of validation of angiogenesis-related gene polymorphisms in hepatocellular carcinoma patients treated with sorafenib: Interim analysis of INNOVATE study

42. PS-043-Dual targeting of G9a and DNM-methyltransferase-1 for the treatment of experimental cholangiocarcinoma

44. FRI-474-AGT gene polymorphisms predict early dose modification of sorafenib for dermatological adverse events: towards tailored medicine for patients with hepatocellular carcinoma

45. Additional file 2: of Prevalence of and risk factors for fatty liver in the general population of Northern Italy: the Bagnacavallo Study

46. Additional file 1: of Prevalence of and risk factors for fatty liver in the general population of Northern Italy: the Bagnacavallo Study

47. Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?

48. Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol

Catalog

Books, media, physical & digital resources